Full coverage· Health· Updated
FDA Approves Teva's New Schizophrenia Drug, Boosting Stock
The FDA has approved Teva Pharmaceutical Industries' new schizophrenia drug, Weltruza, a monthly injection that does not require post-administration medical supervision. The approval led to a roughly 4% rise in Teva's stock on Wall Street.
2 newsrooms · 1 language · since
Plus
What happened
- 01The FDA approved Teva's new schizophrenia drug, Weltruza, a monthly subcutaneous injection.
- 02Weltruza does not require medical supervision after administration, unlike older olanzapine injections.
- 03Teva's stock rose approximately 4% on Wall Street following the FDA's dramatic approval.
- 04The drug targets a significant market of schizophrenia patients in the U.S., including oral olanzapine users.
- 05Investors hope Weltruza will contribute to Teva's growth in branded pharmaceuticals.
Weltruza is based on olanzapine and aims to offer a more convenient treatment option for the estimated 1.5 million Americans receiving schizophrenia medication. Investors are optimistic about the drug's potential to boost Teva's branded pharmaceutical business.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- CentreNone
- Right1
- HarediNone
- ArabNone
- Other1
How it broke
PlusHow it reads
Charged tone, on average across the newsrooms
